BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane

• Published in: European journal of surgical oncology Vol. 42; no. 7; pp. 999 - 1001
• Main Authors: Ishikawa, Takashi, MD, PhD, Narui, Kazutaka, Tanabe, Mikiko, Kida, Kumiko, Oba, Mari S, Yamada, Akimitsu, Ichikawa, Yasushi, Endo, Itaru
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2016
• Subjects: Adult; Aged; Anthracyclines - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Basal-like; BRCA1 Protein - metabolism; BRCAness; Breast cancer; Bridged-Ring Compounds - administration & dosage; Cancer stem cell; Cyclophosphamide - administration & dosage; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin - administration & dosage; Female; Fluorouracil - administration & dosage; Hematology, Oncology and Palliative Medicine; Humans; Immunohistochemistry; Middle Aged; Multiplex Polymerase Chain Reaction; Surgery; Taxoids - administration & dosage; Treatment Outcome; Triple negative; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - metabolism; Triple Negative Breast Neoplasms - pathology; Cancer stem cell; basal-like; Triple negative; Breast Cancer; BRCAness; Breast cancer; Basal-like

Triple negative breast cancer (TNBC) is a heterogeneous disease and is associated with the cancer stem cell (CSC), basal-like, and BRCA1 function deficient (BRCAness) subtypes. We examined these 3 subtypes in TNBC and compared their chemosensitivity against anthracycline or taxane with a special att...